Survey
Quarterly Survey: CGM Systems and Insulin Pumps January 2023
Ticker(s): ABT, MDT, DXCM, PODD, TNDM, SENSSurvey Results include 20 Endocrinologists
How many patients with Diabetes are in your practice?
How many of your patients do you consider eligible for a continuous glucose monitoring (CGM) device system?
How many patients started using a CGM device system for the first time in the last 30 days?
How many patients switched from one CGM device system to a new CGM device system in the last 30 days?
How many patients do you anticipate will start using a CGM device system in the next 30 days?
How much do you anticipate the volume of CGM
device system usage to increase (by %), if at all, over the following?
- 1 year
- 3 years
- 5 years
What is the percentage breakdown of CGM device
system brands you currently use? Please specify between 0-100 for each (sum
to 100%).
- Dexcom
- Eversense
- FreeStyle Libre
- Guardian Connect
- Other
Which of the following brands is your preferred
CGM device?
- Dexcom
- Eversense
- FreeStyle Libre
- Guardian Connect
- Other
You mentioned [x] is your preferred CGM device. Please elaborate on why.
What features being added to future generation CGM devices would have you consider switching manufacturers or significantly shifting share? Please be specific.
What % of your patients on a CGM are also currently using an insulin pump?
What is the percentage breakdown of insulin pump
brands you currently use? Please specify between 0-100 for each (sum to
100%).
- Medtronic MiniMed
- Omnipod Dash
- Tandem t:slim X2
- Other
Which of the following brands is your preferred
insulin pump brand?
- Medtronic MiniMed
- Omnipod Dash
- Tandem t:slim X2
- Other
How have recent insurance coverage changes impacted your brand recommendation? Please be specific.
What is the most exciting new device/area of development in your specialty?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
